Home
4+7 药品带量采购试点执行以来,药品价格切实降低,同时也对药品的供应保障提出了挑战。带量采购是否能在全国全面推行,是否有条件将带量采购延伸到更多品类,医药企业应该如何应对,都是值得探讨和深思的话题。上海美国商会将于2019 年 8 月 22举办带量采购研讨会,邀请来自医药政策学者、行业研究和医疗企业的代表,帮助医疗从业人员及会员企业更为深入地理解政策动向及实施要求。
AmCham Healthcare Committee will hold a discussion on the impact of the volume-based procurement in "4+7 cities" on Aug 22nd, from 12:30-15:20. Speakers include representatives from a healthcare policy research institute, a healthcare consultancy, and pharmaceutical and medtech companies.
活动日程Agenda
12:30 签到
Registration
12:55 开场
Opening Remarks
13:00 上海市卫生和健康发展研究中心主任 金春林——国家"4+7"药品集中带量采购实践与展望
Practice and Outlook for the Volume-Based Procuremnt of Drugs in "4 + 7 Cities" by Jin Chunlin
14:00 毕马威全球战略咨询生命科学行业副总监 许宗迪——"4+7"带量采购的行业影响及应对
Industrial Impact of Volume-based Procurement of Drugs in "4 + 7 Cities" and the Coping Strategy by Jessica Xu
14:20 主题演讲:百时美施贵宝(中国)高级副总裁 中国市场准入总裁 傅旭东
Presentation by Xudong Fu, Vice GM, President of Market Access China, BMS China
14:40 专题讨论 (BD大中华区公共事务及传播部高级总监 韦春艳主持)
Panel Discussion Moderated by Anita (Chunyan) WEI
15:10 观众提问
Audience Q&A
15:20 活动结束
Event Ends
嘉宾Speakers
- 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所)主任 金春林
Jin Chunlin, Director of Shanghai Health Development, Research Center (Shanghai Medical Information Center)
- 百时美施贵宝(中国)高级副总裁 中国市场准入总裁 傅旭东
Xudong Fu, Vice GM, President of Market Access China, BMS China
- 阿斯利康市场准入战略及卓越运营执行总监 曹宇静
Christina Cao, Executive Director, Market Access Strategy & Excellence, AstraZeneca China
- BD大中华区公共事务及传播部高级总监 韦春艳
Anita (Chunyan) WEI, Public Affairs & Communications Director, BD Greater China
- 毕马威全球战略咨询 生命科学行业副总监 许宗迪
Jessica Xu, Associate Director, Global Strategy Group, KPMG